Attitudes, knowledge, and willingness to be vaccinated against seasonal influenza among patients hospitalized with influenza-like-illness: impact of diagnostic testing.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 04 2020
Historique:
pubmed: 8 10 2019
medline: 22 6 2021
entrez: 8 10 2019
Statut: ppublish

Résumé

Influenza vaccine adherence remains low. Communication of virological diagnosis to adults hospitalized with influenza-like illness (ILI) could improve their willingness to be subsequently vaccinated. We prospectively assessed, in adults hospitalized with ILI in six French university hospitals, their willingness to be vaccinated against influenza in the subsequent season, both before and after the communication of RT-PCR Influenza laboratory result; we identified then the determinants associated with the willingness to be vaccinated.A total of 309 patients were included during the 2012-2013 and 2013-2014 influenza seasons; 43.8% reported being vaccinated against influenza for the current season; before communication of influenza laboratory results, 65.1% reported willingness to be vaccinated during the subsequent season. Influenza was virologically confirmed in 103 patients (33.3%). The rate of vaccine willingness increased to 70.4% (

Identifiants

pubmed: 31589554
doi: 10.1080/21645515.2019.1674598
pmc: PMC7227674
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

851-857

Références

Health Psychol. 2007 Mar;26(2):136-45
pubmed: 17385964
Influenza Other Respir Viruses. 2011 Nov;5(6):382-8
pubmed: 21668685
PLoS One. 2016 Jan 29;11(1):e0147931
pubmed: 26824383
Commun Dis Public Health. 2002 Jun;5(2):119-26
pubmed: 12166297
Euro Surveill. 2018 Nov;23(48):
pubmed: 30514414
BMJ Open. 2018 Aug 8;8(8):e021222
pubmed: 30093515
BMC Public Health. 2013 Apr 25;13:388
pubmed: 23617788
Clin Infect Dis. 2013 Jul;57(2):167-75
pubmed: 23532475
Vaccine. 2009 Jan 7;27(2):192-6
pubmed: 18996427
Am J Med. 2001 Oct 15;111(6):474-9
pubmed: 11690574
Vaccine. 2015 Jul 17;33(31):3703-8
pubmed: 26073016
J Infect Dis. 2004 Feb 1;189(3):450-8
pubmed: 14745702
J Infect. 2014 Feb;68(2):125-30
pubmed: 24211414
BMC Public Health. 2006 Oct 11;6:249
pubmed: 17034625
BMC Public Health. 2015 Jul 07;15:618
pubmed: 26148480
Clin Infect Dis. 2012 May;54(10):1427-36
pubmed: 22495079
J Am Geriatr Soc. 2004 Jan;52(1):25-30
pubmed: 14687311
Vaccine. 2016 Apr 19;34(18):2141-6
pubmed: 26854910
BMC Infect Dis. 2015 Aug 21;15:357
pubmed: 26289794
J Natl Med Assoc. 2004 Nov;96(11):1455-61
pubmed: 15586649
Vaccine. 2014 Apr 1;32(16):1841-7
pubmed: 24530926
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
N Z Med J. 2004 May 06;118(1214):U1434
pubmed: 15886725
BMC Public Health. 2015 Dec 29;16:1308
pubmed: 26965449
Infect Control Hosp Epidemiol. 2015 Jul;36(7):841-3
pubmed: 25773676
Health Educ Q. 1984 Spring;11(1):1-47
pubmed: 6392204

Auteurs

Sarah Tubiana (S)

Inserm CIC1425 Bichat, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
IAME, UMR1137, Sorbonne Paris Cité, Paris, France.

Odile Launay (O)

Université Paris Descartes, Sorbonne Paris Cité, Inserm, Paris, France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur, Paris, France.
Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.

Florence Galtier (F)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.
CIC 1411, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.

Pierre Tattevin (P)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.
Faculté de Médecine, Hôpital Pontchaillou, INSERM U835, Université Rennes 1, Rennes, France.

Deborah Postil (D)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.
CIC de Limoges, CHU Dupuytren, Limoges, Limoges, France.

Philippe Vanhems (P)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.
Service d'Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Lyon, and Emerging Pathogens Laboratory - Fondation Mérieux, Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, Lyon, France.

Nezha Lenzi (N)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.

Pierre Verger (P)

Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.
UMR VITROME (Vecteurs, Infections TROpicales et MEditerranéennes), Aix Marseille Univ, INSERM, IRD, Marseille, France.
ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d׳Azur, Marseille, France.

Xavier Duval (X)

Inserm CIC1425 Bichat, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
IAME, UMR1137, Sorbonne Paris Cité, Paris, France.
Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH